GLP1R and congenital isolated hyperinsulinism: Of promise, GLP-1 receptor antagonists have been shown to ameliorate insulin secretion in in vitro and in vivo models of CHI due to K-ATP channel mutations and may become a viable therapeutic option in the future, pending confirmation in human studies (10).